keyword
MENU ▼
Read by QxMD icon Read
search

Subcutaneous immunotherapy

keyword
https://www.readbyqxmd.com/read/28903381/tumor-location-impacts-immune-response-in-mouse-models-of-colon-cancer
#1
Xianda Zhao, Lihua Li, Timothy K Starr, Subbaya Subramanian
Existing preclinical models of human colorectal cancer (CRC) that rely on syngeneic subcutaneous grafts are problematic, because of increasing evidence that the immune microenvironment in subcutaneous tissue is significantly different from the gastrointestinal tract. Similarly, existing orthotopic models that use a laparotomy for establishing grafts are also problematic, because the surgical procedure results in extensive inflammation, thereby creating a nonphysiologic tumor microenvironment. To facilitate the bench-to-bedside translation of CRC immunotherapy strategies, we developed a novel orthotopic model in mice that uses endoscopy-guided microinjection of syngeneic cancer cells...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28902467/eaaci-guidelines-on-allergen-immunotherapy-prevention-of-allergy
#2
REVIEW
Susanne Halken, Desiree Larenas-Linnemann, Graham Roberts, Moises A Calderón, Elisabeth Angier, Oliver Pfaar, Dermot D Ryan, Ioana Agache, Ignacio J I J Ansotegui, Stefania Arasi, George Du Toit, Montserrat Fernandez-Rivas, Roy Geerth van Wijk, Marek Jutel, Jörg Kleine-Tebbe, Susanne Lau, Paolo M Matricardi, Giovanni B Pajno, Nikolaos G Papadopoulos, Martin Penagos, Alexandra F Santos, Gunter J Sturm, Frans Timmermans, R Van Ree, Eva-Maria Varga, Ulrich Wahn, Maria Kristiansen, Sangeeta Dhami, Aziz Sheikh, Muraro Antonella
Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for prevention of i) development of allergic comorbidities in those with established allergic diseases, ii) development of first allergic condition and iii) allergic sensitization...
September 13, 2017: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/28901560/erythema-nodosum-like-panniculitis-mimicking-disease-recurrence-a-novel-toxicity-from-immune-checkpoint-blockade-therapy-report-of-two-patients
#3
Michael T Tetzlaff, Amir A Jazaeri, Carlos A Torres-Cabala, Brinda Rao Korivi, Genie A Landon, Priyadharsini Nagarajan, Adrienne Choksi, Leon Chen, Marc Uemura, Phyu P Aung, Adi Diab, Padmanee Sharma, Michael A Davies, Rodabe Amaria, Victor G Prieto, Jonathan L Curry
Immunotherapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death 1 (PD-1) receptor and its ligand (PD-L1) have demonstrated substantial clinical benefit in patients with clinically advanced solid malignancies. However, autoimmune toxicities are common and often significant adverse events with these agents. While rash and pruritus remain the most common cutaneous complications in treated patients, novel dermatologic toxicities related to immune checkpoint blockade continue to emerge as the number of patients exposed to immunotherapy increases...
September 13, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28898532/immunological-efficacy-of-herbal-medicines-in-prostate-cancer-patients-treated-by-personalized-peptide-vaccine
#4
Noriko Koga, Fukuko Moriya, Kayoko Waki, Akira Yamada, Kyogo Itoh, Masanori Noguchi
This randomized phase II study investigated the immunological efficacy of herbal medicines (HMs) using Hochu-ekki-to and Keishi-bukuryo-gan in combination with personalized peptide vaccination (PPV) for castration-resistant prostate cancer (CRPC). Seventy patients with CRPC were assigned to two arms; PPV plus HMs or PPV alone. Two to four peptides were chosen from 31 peptides derived from cancer antigens for the eight-time subcutaneous injection of PPV according to the patient's human leukocyte antigen type and levels of antigen-specific immunoglobulin G (IgG) titer before PPV treatment...
September 12, 2017: Cancer Science
https://www.readbyqxmd.com/read/28888254/in-season-dosage-adjustment-for-pollen-subcutaneous-immunotherapy-the-controversy-continues
#5
EDITORIAL
Ting F Leung
No abstract text is available yet for this article.
September 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28888176/novel-mechanisms-in-immune-tolerance-to-allergens-during-natural-allergen-exposure-and-allergen-specific-immunotherapy
#6
REVIEW
Willem van de Veen, Oliver F Wirz, Anna Globinska, Mübeccel Akdis
Allergen-specific immunotherapy (AIT) has been used for more than 100 years as a clinical tolerance-inducing and immune tolerance-inducing therapy for allergic diseases and represents a potentially curative method of treatment. AIT functions through multiple mechanisms including early desensitization of basophils and mast cells, regulating T-cell and B-cell responses, changing antibody isotypes, and decreasing activation, mediator release and affected tissue migration of eosinophils, basophils, and mast cells...
September 6, 2017: Current Opinion in Immunology
https://www.readbyqxmd.com/read/28859707/quality-of-life-outcomes-in-patients-who-underwent-subcutaneous-immunotherapy-and-sublingual-immunotherapy-in-a-real-world-clinical-setting
#7
Theresa Schwanke, Eugene Carragee, Maria Bremberg, William R Reisacher
OBJECTIVE: To compare changes in quality of life (QOL) that resulted from sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) in a real-world clinical setting. BACKGROUND: SLIT is established as a viable alternative to SCIT for the treatment of allergic rhinitis. Although comparative trials are increasingly available, few studies have examined QOL outcomes between these two treatments. METHODS: One hundred and five participants who underwent immunotherapy for airborne allergies were enrolled in this prospective, single-center study...
September 1, 2017: American Journal of Rhinology & Allergy
https://www.readbyqxmd.com/read/28853984/next-generation-immunotherapy-for-tree-pollen-allergies
#8
Yan Su, Eliezer Romeu-Bonilla, Teri Heiland
Tree pollen induced allergies are one of the major medical and public health burdens in the industrialized world. Allergen-Specific Immunotherapy (AIT) through subcutaneous injection or sublingual delivery is the only approved therapy with curative potential to pollen induced allergies. AIT often is associated with severe side effects and requires long-term treatment. Safer, more effective and convenient allergen specific immunotherapies remain an unmet need. In this review article, we discuss the current progress in applying protein and peptide-based approaches and DNA vaccines to the clinical challenges posed by tree pollen allergies through the lens of preclinical animal models and clinical trials, with an emphasis on the birch and Japanese red cedar pollen induced allergies...
August 30, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28838649/brachytherapy-attains-abscopal-effects-when-combined-with-immunostimulatory-monoclonal-antibodies
#9
María E Rodriguez-Ruiz, Inmaculada Rodriguez, Benigno Barbes, Lina Mayorga, Alfonso Rodriguez Sanchez-Paulete, Mariano Ponz-Sarvise, José Luis Pérez-Gracia, Ignacio Melero
PURPOSE/OBJECTIVES: Preclinical and clinical evidence indicate that the proimmune effects of radiotherapy can be synergistically augmented with immunostimulatory monoclonal antibodies (mAb) to act both on irradiated tumor lesions and on tumors at distant, nonirradiated sites. We have recently reported that external beam radiotherapy achieves abscopal effects when combined with antagonist anti-PD1 mAbs and agonist anti-CD137 (4-1BB) mAbs. The goal of this work is to study the abscopal effects of radiotherapy instigated by brachytherapy techniques...
August 21, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28821924/-89-zr-labeled-nivolumab-for-imaging-of-t-cell-infiltration-in-a-humanized-murine-model-of-lung-cancer
#10
Christopher G England, Dawei Jiang, Emily B Ehlerding, Brian T Rekoske, Paul A Ellison, Reinier Hernandez, Todd E Barnhart, Douglas G McNeel, Peng Huang, Weibo Cai
PURPOSE: Nivolumab is a human monoclonal antibody specific for programmed cell death-1 (PD-1), a negative regulator of T-cell activation and response. Acting as an immune checkpoint inhibitor, nivolumab binds to PD-1 expressed on the surface of many immune cells and prevents ligation by its natural ligands. Nivolumab is only effective in a subset of patients, and there is limited evidence supporting its use for diagnostic, monitoring, or stratification purposes. METHODS: (89)Zr-Df-nivolumab was synthesized to map the biodistribution of PD-1-expressing tumor infiltrating T-cells in vivo using a humanized murine model of lung cancer...
August 19, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28821461/cutaneous-vaccination-with-coated-microneedles-prevents-development-of-airway-allergy
#11
Akhilesh Kumar Shakya, Chang Hyun Lee, Harvinder Singh Gill
Allergy cases are increasing worldwide. Currently allergies are treated after their appearance in patients. However, now there is effort to make a preventive vaccine against allergies. The rationale is to target patient populations that are already sensitized to allergens but have yet to develop severe forms of the allergic disease, or who are susceptible to allergy development but have not yet developed them. Subcutaneous injections and the sublingual route have been used as the primary mode of preventive vaccine delivery...
August 15, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28819064/the-tumor-microenvironment-regulates-sensitivity-of-murine-lung-tumors-to-pd-1-pd-l1-antibody-blockade
#12
Howard Y Li, Maria McSharry, Bonnie Bullock, Teresa T Nguyen, Jeff Kwak, Joanna M Poczobutt, Trisha R Sippel, Lynn E Heasley, Mary C Weiser-Evans, Eric T Clambey, Raphael A Nemenoff
Immune checkpoint inhibitors targeting the interaction between programmed cell death-1 (PD-1) and its ligand PD-L1 induce tumor regression in a subset of non-small cell lung cancer patients. However, clinical response rates are less than 25%. Evaluation of combinations of immunotherapy with existing therapies requires appropriate preclinical animal models. In this study, murine lung cancer cells (CMT167 and LLC) were implanted either orthotopically in the lung or subcutaneously in syngeneic mice, and response to anti-PD-1/PD-L1 therapy was determined...
September 2017: Cancer Immunology Research
https://www.readbyqxmd.com/read/28814941/a-survey-on-the-perception-of-allergy-specialists-about-the-reimbursed-grass-pollen-tablets-for-seasonal-allergic-rhinitis-in-italy
#13
Ilaria Massaro, Oliviero Rossi, Cristoforo Incorvaia, Carlo Lombardi
BACKGROUND: Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit its prescription. In 2015, the 5-grass pollen tablets was authorized by the European Medicine Agency to treat grass-pollen induced rhinitis and was approved in Italy for full reimbursement. We evaluated the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets...
2017: Clinical and Molecular Allergy: CMA
https://www.readbyqxmd.com/read/28814886/a-practical-guide-to-the-handling-and-administration-of-talimogene-laherparepvec-in-europe
#14
REVIEW
Kevin J Harrington, Olivier Michielin, Josep Malvehy, Isabella Pezzani Grüter, Lorna Grove, Anna Lisa Frauchiger, Reinhard Dummer
Talimogene laherparepvec is a herpes simplex virus-1-based intralesional oncolytic immunotherapy and is the first oncolytic virus to be approved in Europe. It is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage IIIB, IIIC, and IVM1a) with no bone, brain, lung, or other visceral disease. Talimogene laherparepvec is a genetically modified viral therapy, and its handling needs special attention due to its deep freeze, cold-chain requirements, its potential for viral shedding, and its administration by direct intralesional injection...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28811962/an-ror1-bi-specific-t-cell-engager-provides-effective-targeting-and-cytotoxicity-against-a-range-of-solid-tumors
#15
Satyen Harish Gohil, Solange Rosa Paredes-Moscosso, Micaela Harrasser, Marzia Vezzalini, Aldo Scarpa, Emma Morris, Andrew M Davidoff, Claudio Sorio, Amit Chunilal Nathwani, Marco Della Peruta
We have developed a humanized bi-specific T-cell engager (BiTE) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating cells. Focusing initially on pancreatic cancer, we demonstrated that our ROR1 BiTE results in T cell mediated and antigen-specific cytotoxicity against ROR1-expressing pancreatic cancer cell lines in vitro at exceedingly low concentrations (0.1 ng/mL) and low effector to target ratios. Our BiTE prevented engraftment of pancreatic tumor xenografts in murine models and reduced the size of established subcutaneous tumors by at least 3-fold...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28802075/overcoming-severe-adverse-reactions-to-venom-immunotherapy-by-using-anti-ige-antibodies-in-combination-with-a-high-maintenance-dose
#16
Eva Stretz, Eva Maria Oppel, Räwer Helen-Caroline, René Chatelain, Sebastian Mastnik, Bernhard Przybilla, Franziska Ruëff
BACKGROUND: An omalizumab treatment and a high maintenance venom dose may both help to prevent recurrent systemic allergic reactions (SAR) to venom immunotherapy (VIT). The effectiveness of this combination therapy, however, is unclear. OBJECTIVE: We wanted to explore the possibility whether a temporary treatment with the anti-IgE antibody omalizumab, combined with a VIT using an elevated maintenance dose of >100 μg venom may establish a permanent tolerance of maintenance VIT...
August 12, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28801026/quadruple-immunotherapy-of-bacillus-calmette-gu%C3%A3-rin-interferon-interleukin-2-and-granulocyte-macrophage-colony-stimulating-factor-as-salvage-therapy-for-non-muscle-invasive-bladder-cancer
#17
Ryan L Steinberg, Kenneth G Nepple, Kyla N Velaer, Lewis J Thomas, Michael A O'Donnell
BACKGROUND: Bacillus Calmette-Guérin (BCG) is the most effective initial intravesical therapy for high-grade non-muscle invasive bladder cancer, but many patients still fail. Combination intravesical BCG and interferon (IFN) will salvage some patients but results remain suboptimal. OBJECTIVE: We hypothesized that further immunostimulation with intravesical interleukin-2 and subcutaneous granulocyte-macrophage colony-stimulating factor may improve response to intravesical BCG and IFN in patient with prior BCG failure(s)...
August 8, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28795532/a-combination-of-anti-pd-l1-mab-plus-lm-llo-e6-vaccine-efficiently-suppresses-tumor-growth-and-metastasis-in-hpv-infected-cancers
#18
Po-Lin Lin, Ya-Min Cheng, De-Wei Wu, Yu-Ju Huang, Hun-Chi Lin, Chih-Yi Chen, Huei Lee
PD-1/PD-L1 immunotherapy is viewed as having clinical benefits in advanced cancers but is effective in only a few patients, suggesting that an efficient combination approach is needed to improve efficacy. Immunohistochemistry analysis indicated that PD-L1 expression was correlated with the E6 expression in tumors from 122 lung cancer patients. The poorest survival occurred in PD-L1-positive/E6-positive tumor. PD-L1 expression was increased by the expression of E6, but not the E7, oncoprotein in lung and cervical cancer cells...
August 9, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28794855/allergen-immunotherapy-for-allergic-rhinoconjunctivitis-a-systematic-overview-of-systematic-reviews
#19
REVIEW
Ulugbek Nurmatov, Sangeeta Dhami, Stefania Arasi, Graham Roberts, Oliver Pfaar, Antonella Muraro, Ignacio J Ansotegui, Moises Calderon, Cemal Cingi, Stephen Durham, Roy Gerth van Wijk, Susanne Halken, Eckard Hamelmann, Peter Hellings, Lars Jacobsen, Edward Knol, Desiree Larenas-Linnemann, Sandra Y Lin, Vivian Maggina, Hanneke Oude-Elberink, Giovanni Pajno, Ruby Panwankar, Elideanna Pastorello, Constantinos Pitsios, Giuseppina Rotiroti, Frans Timmermans, Olympia Tsilochristou, Eva-Maria Varga, Jamie Wilkinson, Andrew Williams, Margitta Worm, Luo Zhang, Aziz Sheikh
BACKGROUND: The European Academy of Allergy and Clinical Immunology (EAACI) is developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis (ARC). To inform the development of recommendations, we sought to critically assess the systematic review evidence on the effectiveness, safety and cost-effectiveness of AIT for ARC. METHODS: We undertook a systematic overview, which involved searching nine international biomedical databases from inception to October 31, 2015...
2017: Clinical and Translational Allergy
https://www.readbyqxmd.com/read/28765817/allergen-specific-intralymphatic-immunotherapy-in-human-and-animal-studies
#20
REVIEW
Seon Tae Kim, So Hyun Park, Sang Min Lee, Sang Pyo Lee
Clinical trials of intralymphatic immunotherapy (ILIT) have been performed to overcome the limitations of long-term therapy and the local or systemic hypersensitivity reactions in conventional allergen-specific immunotherapy, including subcutaneous or sublingual immunotherapy. Additionally, several animal studies of ILIT have been conducted in the form of translational or veterinary research. We conducted a literature review to examine the treatment efficacy and adverse effects of ILIT.
July 2017: Asia Pacific Allergy
keyword
keyword
54124
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"